In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
 Pascal Vranckx
Speaker
Pascal Vranckx

Heart Centre Hasselt, Hasselt (Belgium)

Specialities : Acute Cardiac Care , Acute Cardiac Care, Interventional Cardiology

Dr. Pascal Vranckx is a Clinical Consultant in Interventional Cardiology and Medical Director of Cardiac Critical Care Services at the Hartcentrum Hasselt in Belgium. He is professor at the faculty of medicine and life sciences at the University of Hasselt, Belgium. Dr. Vranckx is also board member of the European Cardiovascular Research Institute, in Rotterdam, The Netherlands. Previously Dr. Vranckx was clinical director of the Cardiac Intensive Care Unit at the Thoraxcenter, Erasmus Medical Center, Rotterdam. Dr. Vranckx is past-secretary of the Acute Cardiac Care Association (ACCA) and is also a chair of the medical committee of the Red Cross Flanders, Belgium. Dr. Vranckx has authored over 100 publications and 11 books and is an co-editor of the ESC Textbook of Acute Cardiology and Intensive Care Medicine 2015 and associate editor of the ACCA clinical decision making toolkit.

27 presentations from this speaker

Balancing antithrombotic therapy in atrial fibrillation patients undergoing cardiovascular interventions: update on clinical evidence and guideline recommendations.

Congress : Acute Cardiovascular Care 2019

  • Session : Safety implications of anticoagulation therapy in acute cardiovascular care
  • Speaker : P Vranckx (Hasselt,BE)
  • Sponsored by Daiichi Sankyo Europe GmbH

ENTRUST-AF PCI trial in context with other non-vitamin K antagonist oral anticoagulant trials in percutaneous coronary intervention practice

Congress : ESC Congress 2019

  • Session : Antithrombotic therapy in atrial fibrillation patients undergoing PCI: where do we stand?
  • Speaker : P Vranckx (Hasselt,BE)
  • Daiichi Sankyo Europe GmbH

State of the Art: Diagnosis and management of unstable myocardial infarction

Congress : Acute Cardiovascular Care 2019

  • Session : Unstable myocardial infarction: diagnose, treat, and collaborate!
  • Speaker : P Vranckx (Hasselt,BE)

The trial of the trial: Assessing GLOBAL LEADERS innovations, limitations and implications for clinical practice - Introduction.

Congress : Acute Cardiovascular Care 2019

  • Session : The trial of the trial: Assessing GLOBAL LEADERS innovations, limitations and implications for clinical practice
  • Speaker : P Vranckx (Hasselt,BE)

Advanced management of patients with cardiogenic shock: translating science to practice .

Congress : ESC Congress 2018

  • Session : Caring for patients with acute cardiovascular disease together.
  • Speaker : P Vranckx (Hasselt,BE)
  • Acute Cardiovascular Care Association (ACCA)

Balancing benefit and risk of combining oral anticoagulation and antiplatelet agents in patients with atrial fibrillation: current and future evidence.

Congress : Acute Cardiovascular Care 2018

  • Session : Cardiovascular interventions in patients with atrial fibrillation: an expanding clinical landscape
  • Speaker : P Vranckx (Hasselt,BE)
  • Sponsored by Daiichi Sankyo Europe GmbH

Discussion - Cardiovascular interventions in patients with atrial fibrillation: an expanding clinical landscape.

Congress : Acute Cardiovascular Care 2018

  • Session : Cardiovascular interventions in patients with atrial fibrillation: an expanding clinical landscape
  • Speaker : M Lettino (Milano,IT), K Huber (Vienna,AT), P Vranckx (Hasselt,BE)
  • Sponsored by Daiichi Sankyo Europe GmbH

It is time to reconsider aspirin as a routine therapy for secondary prevention after STEMI - PRO.(Via ZOOM)

Congress : Acute Cardiovascular Care 2018

  • Session : Great debate on STEMI: current controversies on antiplatelet management after the acute phase
  • Speaker : P Vranckx (Hasselt,BE)

It is time to reconsider aspirin as a routine therapy for secondary prevention after STEMI - Rebuttal PRO. .(Via ZOOM)

Congress : Acute Cardiovascular Care 2018

  • Session : Great debate on STEMI: current controversies on antiplatelet management after the acute phase
  • Speaker : P Vranckx (Hasselt,BE)

Pathophysiology and initial drug treatment..Presentation given by Prof A Sionis

Congress : Acute Cardiovascular Care 2018

  • Session : Open questions in cardiogenic shock
  • Speaker : P Vranckx (Hasselt,BE)

Terminal heart failure - The "when" and "how" of mechanical cardiac support

Congress : ESC Congress 2018

  • Session : Cardiac intensive care essentials: review, update, and State of the Art in 2018
  • Speaker : P Vranckx (Hasselt,BE)

Acute cardiac care in stable and unstable STEMI.

Congress : ESC Congress 2017

  • Session : ESC Guidelines 2017 - AMI-STEMI
  • Speaker : P Vranckx (Hasselt,BE)

Focused update on dual antiplatelet therapy

Congress : ESC Congress 2017

  • Session : Congress Condensed - ESC Clinical Practice Guidelines 2017
  • Speaker : P Vranckx (Hasselt,BE)

Pulmonary artery catheter and PICCO

Congress : ESC Congress 2017

  • Session : First night in the ICU - Don't be afraid of the machines
  • Speaker : P Vranckx (Hasselt,BE)

Rapid response teams to prevent in-hospital cardiac arrest

Congress : ESC Congress 2016

  • Session : Teams in cardiopulmonary resuscitation
  • Speaker : P Vranckx (Hasselt,BE)
  • Joint with the European Resuscitation Council

What is the optimal mechanical support device in 2016 ?

Congress : Acute Cardiovascular Care 2016

  • Session : Cardiogenic shock
  • Speaker : P Vranckx (Hasselt,BE)

When and who to refer for implantable assist devices

Congress : ESC Congress 2016

  • Session : Management of acute coronary syndromes patients in cardiogenic shock
  • Speaker : P Vranckx (Hasselt,BE)

Complex three vessel disease and left main stenosis, Syntax II and EXCEL will change the landscape - PRO

Congress : ESC Congress 2015

  • Session : From pure revascularisation to concomitant mitral valve repair: controversies and challenges
  • Speaker : P Vranckx (Hasselt,BE)
  • ESC and the European Association for Cardio-Thoracic Surgery

Complex three vessel disease and left main stenosis, Syntax II and EXCEL will change the landscape - REBUTTAL PRO.

Congress : ESC Congress 2015

  • Session : From pure revascularisation to concomitant mitral valve repair: controversies and challenges
  • Speaker : P Vranckx (Hasselt,BE)
  • ESC and the European Association for Cardio-Thoracic Surgery

Focus on multiorgan dysfunction.

Congress : ESC Congress 2014

  • Session : STEMI complicated by cardiogenic shock
  • Speaker : P Vranckx (Hasselt,BE)

Percutaneous support: when and how.

Congress : ESC Congress 2014

  • Session : Management of cardiogenic shock related to acute coronary syndromes
  • Speaker : P Vranckx (Hasselt,BE)

Rivaroxaban in elective percutaneous coronary intervention to treat stable coronary artery disease.

Congress : ESC Congress 2014

  • Session : Thrombosis and anticoagulation - II
  • Speaker : P Vranckx (Hasselt,BE)

Clinical validation of BARC definitions of bleeding after an ACS in the TRACER trial

Congress : ESC Congress 2013

  • Session : Antithrombotic therapy: unsolved problems
  • Speaker : P Vranckx (Hasselt,BE)

Panel discussion.

Congress : ESC Congress 2013

  • Session : Moving targets in interventional cardiology
  • Speaker : M Noc (Ljubljana,SI), P Vranckx (Hasselt,BE), H Thiele (Leipzig,DE)

Panel discussion.

Congress : ESC Congress 2013

  • Session : Moving targets in interventional cardiology
  • Speaker : D Dudek (Krakow,PL), M Noc (Ljubljana,SI), P Vranckx (Hasselt,BE)

Why are we seeing the renaissance of extracorporeal membrane oxygenation?

Congress : ESC Congress 2013

  • Session : Cardiogenic shock - multimodality device therapy
  • Speaker : P Vranckx (Hasselt,BE)

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are